Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One ...
The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement ...
Project Vital is a statewide initiative to invest in research, workforce development, and biotech startups, positioning Virginia as a leader in biotechnology. Virginia Tech, Carilion Clinic, and the ...
Dr. Singh urged states to establish ‘BioE3 Cells’ in collaboration with the Centre through the Department of Biotechnology ...
New York City Mayor Eric Adams has declared that he is “no longer facing legal questions” after the Trump administration ...
Stratos Wealth Partners LTD. trimmed its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 17.9% ...
Brent Sabatini, the Senior Vice President and Chief Accounting Officer at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 1,562 shares of the company's common stock. According to InvestingPro data ...
Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Hosted on MSN18h
New Medical Tech That Could Save LivesVarshavski: I asked a bunch of different specialists what's the one medical breakthrough they're excited about in their ...
BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...
Scotland's IBioIC welcomed more than 100 new members to its network in 2024, reflecting the growth in the sector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback